NCT05702229 2026-03-18
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
AstraZeneca
Phase 2 Recruiting
Clinical Trials
11 trialsNCT06256328 2026-03-13
A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Ono Pharmaceutical Co. Ltd
Phase 2 Active not recruiting
NCT07069712 2026-03-10
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
AstraZeneca
Phase 2 Recruiting
NCT03221426 2026-03-09
KEYNOTE-585
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05568095 2026-03-04
STAR-221
Arcus Biosciences, Inc.
Phase 3 Active not recruiting
NCT05152147 2026-02-27
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3 Active not recruiting
NCT06532006 2026-02-27
A Phase â…¢ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Shanghai Henlius Biotech
Phase 3 Recruiting
NCT07432295 2026-02-25
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
I-Mab Biopharma US Limited
Phase 2 Recruiting
NCT04430738 2026-02-24
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Phase 2 Active not recruiting
NCT07431281 2026-02-24
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
NCT04379596 2026-02-23
DG-03
AstraZeneca
Phase 2 Recruiting